![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Renal Safety Through 96 Weeks in a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults With HIV-1
|
|
|
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Frank A. Post1; Ciaran J. McMullan2; Giovanni Di Perri3; Jean-Michel Molina4; Stephanie O. Klopfer2; Anjana Grandhi2; Karen Eves2; Deborah Hepler2; Carey Hwang2; Todd A. Correll2
King's College Hospital NHS Foundation Trust, London, UK; 2Merck & Co., Inc., Kenilworth, NJ, USA; 3University of Turin, Turin, Italy; 4University of Paris Diderot and St-Louis Hospital, Paris, France
![1005201](../images/100520/100520-8/1005201.gif)
![1005202](../images/100520/100520-8/1005202.gif)
![1005203](../images/100520/100520-8/1005203.gif)
![1005204](../images/100520/100520-8/1005204.gif)
![1005205](../images/100520/100520-8/1005205.gif)
![1005206](../images/100520/100520-8/1005206.gif)
![1005207](../images/100520/100520-8/1005207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|